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ENZYME LINKED IMMUNOSORBENT ASSAY FOR DIAGNOSIS 










BACKGROUND: Development of “combination” assays detecting in parallel, within a single test, 
Hepatitis C Virus (HCV) antigens and antibodies, not only reduces the window period in HCV-infection 
but also costs. Reduction of costs is important for developing countries where money and personal 
resources are limited.  
METHODS: We compared the Monolisa® HCV Antigen-Antibody Ultra (Bio-Rad Laboratories Limited, 
Marnes La Coquette, France) with the AXSYM HCV version 3.0 (Abbot Diagnostics, Germany)-the latter 
assay detecting only antibodies to HCV. Seventy three HCV-PCR positive and negative samples were 
tested.  
RESULTS: Although the two assays showed comparable results, two samples from a bone marrow 
transplant (BMT) patient of viral loads 7.8 x 10
5
 and 8.9 x 10
6
 IU/mL could not be detected by the 
Monolisa® HCV Antigen-Antibody Ultra assay. Failure to detect the two samples with viral loads 
considered above threshold of detection for antigen proteins suggested a lack of sensitivity by this assay 
to discover viral capsid protein in patient samples. Genotyping of these samples revealed genotype 1b, a 
HCV-subtype which is widespread and should thus be easily detected.  
CONCLUSION: We conclude that although this assay depicts high sensitivity and specificity in detecting 
antibodies to HCV, it seems not to add further benefit in our study population to detect HCV infections 
by enhanced sensitivity due the potential contingency to trace viral capsid antigens.  
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INTRODUCTION   
 
Hepatitis C virus (HCV) remains a major health 
care burden globally. It is currently estimated that 
170 million people suffer from HCV chronic 
infections worldwide (1). The highest prevalence 
rates are still reported in Africa, Eastern 
Mediterranean, South East Asia and the Western 
Pacific. True incidence rates across the world 
continue to fluctuate. In developing countries 
exact incidence rates have been difficult to 
calculate given the asymptomatic, often latent 
nature of the disease prior to clinical presentation. 
Further prevalence rates across the developed 
world are changing since more countries are now 
aware of transfusion-related HCV. Many regions 
still use blood donors to report the prevalence of 
HCV infection. Using blood donors may 
underestimate the true prevalence since they 
represent generally a highly selected population. 
Studies show intravenous drug use as the 
leading risk factor for the spread HCV (2, 3) while 
others include transfusion of blood and blood 
products as well as hemodialysis (4-7) and sexual 
route of transmission (8-10). Therefore, the 
complexity and uncertainty related to the 
geographic distribution, chronic HCV, 
determination of its associated risk factors and 
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evaluation of cofactors accelerating its 
progression, underscore the difficulties in global 
prevention and control of HCV.   
Contrary to industrialized countries where 
anti-HCV screening and mini-pool nucleic acid 
amplification testing (NAT) is done on all 
collected blood hence a reduction in transmission, 
transfusion related transmission remains critical 
for many developing countries. The fact that HCV 
shows no clear clinical signs during the long 
window period further complicates the risk of 
transmission through other routes to the general 
population. Infection with HCV in Human 
Immunodeficiency Virus (HIV) infected could 
lead to an increased rate of progression to acquired 
immune-deficiency syndrome (AIDS), hamper 
immune reconstitution of patients and aggravate 
the risk of hepa-toxicity especially in patients on 
HIV treatment.  Indeed, HCV infection has been 
reported to increase the number of complications 
in persons co-infected with HIV (11). With the 
increasing number of cases of HIV/HCV co-
infection in Africa (12-16), there is a need for 
early HCV diagnosis so as to enhance optimum 
treatment and management of HIV patients. This 
would reduce possible complications resulting 
from dual infections. 
Apart from early detection of HCV infection, 
combined antigen/antibody ELISA assays would 
be used for detection in the immune-suppressed or 
immune-deficient patients including HIV positive 
or patients with a history of bone marrow 
transplantation (BMT). Such patients show 
increased risk of serious veno-occlusive disease 
(VOD) of the liver (17-21). With recovery of 
cellular immunity after transplantation, severe 
hepatitis and fulminant liver failure may occur 
(22). In the absence of humoral or immediate cell 
mediated response in these patients, a rapid viral 
replication would lead to the production of various 
antigens. Today with BMT history of over 30 
years, infection in long term survivors requires 
regular HCV follow-up assays and viral load tests.  
This study aimed at evaluating the diagnostic 
performance of Monolisa® HCV Ag-Ab ULTRA 
(Bio-Rad) ELISA kit for simultaneous detection of 





MATERIALS AND METHODS 
Study design: The study involved both 
retrospective and prospective laboratory-based 
analysis of 73 (47 positive and 26 negative) 
archived plasma samples between May and 
September, 2012. The positive samples included a 
panel of 7 samples obtained at different time 
points from a BMT patient. Samples had been 
stored at -20°C before analysis and were used with 
permission from the virology department of the 
Max von Pettenkofer-Institute in Munich, 
Germany, where testing of the same samples was 
done.  
Test principle for Monolisa® HCV Ag-Ab 
ULTRA detection kit: Monolisa® HCV Ag-Ab 
ULTRA assay is an enzyme immunoassay 
designed to detect both the capsid antigen and 
antibodies in serum or plasma. A micro-plate is 
coated with monoclonal antibodies against the 
capsid protein of HCV and two recombinant 
proteins produced in E. coli; one from the NS3 
region (genotype 1 and 3a), and a recombinant 
antigen from the non-structural region NS4. A 
mutated peptide from the capsid structural region 
is also immobilized on the plate. Two conjugates 
are involved; conjugate 1 (R6) is a mouse 
biotinylated monoclonal antibody against the 
HCV capsid (it does not react with the HCV 
capsid mutated peptide coated on the micro-plate), 
Conjugate 2 (R7) is a mouse peroxidase-labeled 
antibody to human IgG and peroxidase-labeled 
streptavidin. 
Test evaluations and sample characterization: 
The samples were first tested by “antibody only” 
ELISA kits (AxSYM HCV version 3.0 (Abbott 
Diagnostics, Germany) and Ortho® HCV 3.0 with 
Enhanced SAVe (Ortho-Clinical Diagnostics, 
United Kingdom)) before amplification by PCR. 
Samples giving conflicting results by the ELISA 
kits were tested by western blot (INNO-LIA HCV 
score, Innogenetics® N.V, Belgium). Plasma 
HCV RNA quantification was performed by real 
time PCR using an in-house assay with internal 
positive controls.  Based on the results, samples 
were categorized as; (1) HCV-RNA positive, (2) 
antibody positive-HCV-RNA negative, (3) HCV 
antibody negative-HCV-RNA negative, and (4) 
HCV-RNA positive BMT serial samples obtained 
over a period of 276 days.  
Sensitivity: The 47 positive samples (31 HCV-
RNA positive, 9 antibody positive- HCV-RNA 




negative and 7 HCV-RNA positive serial samples) 
were used to evaluate the sensitivity of the assay. 
The 31 HCV-RNA positive samples were of 
genotypes 1 to 4 and a “mixed” genotype, with 
viral loads from 4 x 10
4
 IU/mL to 29 x 10
6 
IU/mL, 
whereas the 7 serial samples were of genotype 1b 
measuring from 3 x 10
3
 to 10 x 10
6
 IU/mL. 
Genotyping of plasma samples was determined by 
Restriction Fragment Length Polymorphism 
(RFLP), and where RFLP failed, the samples were 
sequenced and blasted in the HCV database for 
determination.  Genotypes determined included 1a 
(4/31), 1b (7/31), 2a (5/31), 2b (1/31), 3a (6/31), 4 
(7/31) and “mixed” [1a, 3b and 4] (1/31). 
Specificity: Specificity was evaluated using 26 
negative samples selected from a group of patients 
with no known risk of HCV infection who 
attended the hospital for regular checkups.  
Test procedures: Test procedure for Monolisa® 
HCV Ag-Ab ULTRA was performed following the 
instructions of the manufacturer. Briefly, the 
diluted washing solution and the working antigen 
positive control were freshly prepared. The 
following components were added into the plate; 
100µL of conjugate 1(R6) was added into each 
well, 50µL of negative control serum (R3) in well 
A1, 50µL of antibody positive control serum (R4) 
into B1, C1 and D1, 50µL of working antigen 
positive control into well E1 and 50µL of patient 
samples into in well F1 and the succeeding wells. 
The materials were mixed for 5 seconds covered 
with an adhesive film and incubated for 1 hour at 
37°C. After incubation the plates were washed 
five times using 400µL of washing solution before 
addition of 100µL of conjugate-2 solution (R7) 
and a further incubation at 37°C for 30 minutes. 
After another 5-step wash, 80µL of freshly 
prepared enzymatic development solution was 
added followed by a 30 minutes’ incubation in the 
dark at room temperature. The reaction was finally 
stopped using 100µL stopping solution (R10) and 
the optical density (OD) measured at 450/620 nm 
using a “Sunrise” ELISA reader. 
The presence or absence of antibodies to 
HCV or/and HCV capsid antigen was determined 
by comparing the recorded absorbance for each 
sample with the calculated cut-off value. The cut-
off value was determined by dividing the mean of 
the OD readings for the three positive controls by 
4. Readings below the cut-off were considered 
non-reactive; samples below the cut-off value by 
less than 10% were retested. Samples above the 
cut-off values were considered initially reactive 
and retested in duplicate before a final 
interpretation was made. Results were compared 
with those of AxSYM HCV version 3.0 for the 
same samples. 
Data analysis: Data were analyzed using 
GraphPad prism 5 statistical software. Pearson´s 
correlation (R
2
) was used to correlate viral load 
against OD for ELISA assays. Sensitivity and 
specificity of the assays were tested using PCR 




Overall performance of Monolisa® HCV Ag-Ab 
ULTRA assay kit (sensitivity, specificity and 
predictive values). 
As shown in table 1, the two assays equally 
detected all the 31 HCV-RNA positive samples, 
and for each assay 4 out of 7 serial samples. 
Results, however, varied within HCV-RNA 
negative-antibody positive and the HCV-RNA 
negative-antibody negative samples.   
 
 
Sensitivity and Specificity: In the first case, the 
overall sensitivity and specificity was calculated 
for the two assays using the 73 samples. As shown 
in table 2 a higher sensitivity was realized with 
Table 1: Suspected Hepatitis C samples tested with AXSYM and  Monolisa Ag/Ab ELISA kits (n=73) 
 
Test samples AXSYM Monolisa® HCV Ag-Ab 
Sample type Total  Reactive Non-Reactive Reactive Non- Reactive 
PCR positive samples 31 3(100%)       0 31(100%)         0 
Antibody positive- PCR  negative 9 9(100%)       0  8(88.9%)        1(11.1%) 
HCV negative samples 26 1(3.8%)    25(96.2)      0        26(100%) 
Bonemarrow transplant patient 7 4(57.1%)    3(42.9%) 4(57.1%)         3(42.9%) 
Total 73 45 28 43        30 





AxSYM HCV version 3.0, and a likelihood ratio 
of 24.34, compared to Monolisa® HCV Ag-Ab 
ULTRA assay kit. Since false negative results only 
occurred in the BMT panel, a second analysis was 
done excluding this panel mainly to observe the 
performance of the assay on individual samples 
devoid of the effect of the serial samples. There 
was a general improvement in sensitivity in both 
assays, once more a likelihood ratio of 26.0 was 
realized for AxSYM HCV version 3.0. Table 2 
shows sensitivity and specificity results for the 
two ELISA assays. An improved sensitivity 
results was obtained for both assays when the 
samples from the BMT patient were excluded 
from the analysis. Likelihood ratios of 24.3 and 
26.0 were obtained in the general and partial 
analyses respectively.  
Table 2: Sensitivity, specificity and predictive values of Monolisa Ag/Ab and AxSYM HCV version 3.0 
ELISA assays 
 





    PPV %    NPV  % 
Monolisa® HCV Ag-Ab ULTRA assay     
              Overall Analysis 91.5(43/47)   100(26/26)      100     86.7 
 (79.6 - 97.6) (86.8 -100) (91.8 - 100) (69.3 – 96.2) 
     
             Partial analysis** 97.5(39/40)      100      100      96.3 
  (86.8 - 99.9) (86.8 - 100) (91-100) (81 - 99.9) 
AxSYM HCV version 3.0     
          Overall Analysis 93.6       96.2      97.8      89.3 
 (82.5 - 98.7) (80.4 - 99.9) (88.2 -99.9) (71.8 -99.7) 
     
          Partial analysis**  100(40/40)       96.1        97.6       100 
 (91.2 - 100) (80.4 -99.9) (87.1 – 99.9) (86.3 -100) 
** 7 samples in the BMT sample panel excluded from the analysis 
 
Viral load versus optical density: Evaluation of 
Monolisa® HCV Ag-Ab ULTRA assay and 
AxSYM ELISA kits was further done with 
samples of different viral loads. The samples 
included those below the theoretical threshold of 
260,000 IU/mL (approximately 13.7 pg of total 
HCV core antigen)(23, 24) calculated for 
Monolisa® HCV Ag-Ab ULTRA assay kit (25). No 
significant correlation was observed between viral 
loads and the optical density; r (32) = .097; p=.60 
for Monolisa® HCV Ag-Ab ULTRA assay (Fig. 1) 
and r (32) = .082; p=.66 for AxSYM HCV version 
3.0 (Fig. 2). The finding confirmed the earlier 
observation during the study where some samples 
of 8.9 x10
6 
IU/mL and 7.8 x 10
5
 IU/mL were not 



















Fig 1. Optical density versus viral load for
AxSYM Ab ELISA (n=32)








Figure 2 shows no correlation (R(32)= 0.082) between viral load and optical
density signals for AxSYM antibody ELISA. One sample close to 1x10
7
IU/mL
(circled in a red ring) could not be detected as the optical density (OD) value
was found below the cut off value (s/co = 1.0), whereas one sample below
1x10
5








































Fig 2: Optical density versus viral load for AxSYM Ab 
ELISA (n = 32) 














Figure 1 shows no correlation (R
2 
(32) = 0.097) between viral load and optical density signals for Monolisa Ag-Ab 
Ultra assay. One sample of approximately 10 x 10
6
 IU/mL was not detected (red arrow) since OD fell below the cut off 
value, whereas one sample below 1 x 10
5




















Figure 2 shows no correlation (R
2
 (32) = 0.082) between viral load and optical density signals for AxSYM, antibody 
ELISA. One sample of approximately 10 x 10
6
 IU/mL (circled in a red ring) was not detected since the OD was below 
the cut off va ue (s/co = 1.0), whereas on sample below 1 x 10
5
 IU/mL was d tected. 
 
Samples from a Bone Marrow Transplant (BMT) 
patient: Since immune reconstitution after bone 
marrow transplantation has been studied (26-33) 
and found to vary between 6 months to over 2 
years, detection of antibodies during this period 
remains minimal. The BMT samples were used to 
evaluate the efficacy in antigen detection by 
Monolisa® HCV Ag-Ab ULTRA assay. This 
capacity would be important if this assay would be 
used in immunocompromised patients. The BMT 
samples were of genotype 1b, a genotype that is 
less responsive to alpha-interferon therapy 
compared to genotypes 2 and 3 (34), and is mainly 
found in the Americas, Europe and parts of Asia. 
All the detections were only observed in the pre-
BMT samples (Fig. 3) with no detection on 
samples collected up to 276 days (about 9 months) 
post transplant. The ODs post transplant was 
below the cut-off-limits (0.5 and 1) of the 2 
 Fig 1. Optical density versus viral load for
Monolisa Ag-Ab Ultr (n=32)










Figure 1 hows no corre ation (R(32)= 0.097) between viral load and
optical de sity signals for Monolisa Ag-Ab Ultra. One sample close to
1x10
7
IU/mL could not be detected as the optical density (OD) value was
found below the cut off value (1.0 nm), whereas one sample below 1x10
5
IU/mL generated a positive signal above the cut off value












Fig 1: Optical density versus viral load for 














R2 = 0.097 















Fig. 3 Detection of HCV in plasma of a BMT patient




























Monolisa® HCV Ag-Ab ULTRA
 






Fig. 3a Monolisa® HCV Ag-Ab ULTRA on BMT patient



















threshold of 1.0 (s/co)









Fig. 3b  AxSYM version 3.0 on BMT patient



























threshold of 1.0 (s/co)




























Figure 3 shows results of ELISA tests from plasma of a BMT patient obtained pre and post bone marrow 
transplant. All samples obtained before bone marrow transplant were positively detected (Figure 3a and 





ELISA assays combining antibody and antigen 
detections in a single kit have been developed and 
introduced in the field of HIV diagnosis (35). 
Introduction of similar assays for detecting acute 
HCV infection, which previously relied on 
classical serological methods (36), offers 
advantages over the existing antibody “only” 
assays mainly on early detection and detection in 
immunocompromised population.   
Despite the anticipated advantages of 
“combination” assays, we report the failure of 
Monolisa® HCV Ag-Ab ULTRA to detect three 
PCR positive samples of genotype 1b from a BMT 
patient, despite the high viral loads in 2 samples. 
A similar study (25) also reported failure of 
Monolisa® HCV Ag-Ab ULTRA assay to detect a 
genotype 1b (8.19 x 10
6
 IU/mL) and a genotype 3a 
(7.76 x 10
6
 IU/mL) samples. Further a genotype 4 
HCV positive sample could not be detected by this 
assay despite the fact that the virus had a normal 
core sequence (37).  These findings of failure to 
detect samples with high viral loads have a 
significant implication for this assay designed to 
detect both antigen and antibody proteins. 
Arguably, HCV as a member of Flaviviridae 
family has an icosahedral capsid of T3 or T4 
symmetry with 180 or 240 core protein subunits. 
Since one RNA genome contains 240 subunits of 
core protein of a molecular mass 19 x 10
3
 Da, one 
picogram (pg) of virus core corresponds to 1.3 x 
10
5
 HCV genome molecules. Some studies even 
indicate lower ratios of viral particles per pg of 
proteins, for example in one study the ratio never 
exceeded 2 x 10
4
 IU/mL (6 x 10
4
 




genomes/pg)(38), whereas another study estimated 
an average 8 x 10
3
 IU/mL per pg of core proteins 
(5 x 10
3
 IU/mL to 1.2 x 10
4
 IU/mL per pg of 
proteins) (39). The latter findings were supported 
by our in-house results (unpublished data) which 
showed an antigen detection limit of 1.5pg/mL for 
the core antigen corresponding to 1.6 x 10
4
 
IU/mL. Based on these calculations, we note that 
less than 15% of core proteins are associated with 
HCV particles containing RNA and 240 core 
subunits, whereas the remaining 85% of the 
protein are associated with structures lacking HCV 
RNA. These structures have previously been 
described (40). The latter argument would explain 
the results realized in figure 1 where 2 samples 
with viral loads below the theoretical threshold 
were easily detected by this assay. These samples 
also showed higher optical signals compared to 
some samples with higher viral loads.  
We however note that a similar trend of 
results shown in figure 1 was also realized in 
figure 2 where the 2 samples were again detected 
by the “antibody only” kit. The similarity in the 
trend of detection by the 2 different assays pointed 
towards the fact that the optical signals for these 2 
samples were generated by the antibodies as 
opposed to antigens in the samples. This argument 
is strengthened by the fact that, upon generation of 
antibodies by the immune system, viral loads 
normally decline. The above argument therefore 
supports the view that Monolisa® HCV Ag-Ab 
ULTRA assay, as composed, is inclined to 
antibody detection than core antigens. 
The two samples with viral loads above the 
threshold limit which were not detected by 
Monolisa® HCV Ag-Ab ULTRA assay similarly 
elicit various arguments about the assay. Some 
studies have failed to demonstrate the presence of 
antigens in RNA positive sera, for example, in one 
study,(41) antigens were not detected in sera 
despite measuring between 10
5
 IU/mL and 8.2 x 
10
5
 IU/mL. In the latter study, some samples 
below 8.5 x 10
5
 IU/mL were detected. Other 
studies have also demonstrated that analytical 
sensitivity of antigen assays does not constantly 
correspond the HCV- RNA titer (42). In the latter 




 IU/mL remained 
negative, while 12 sera below 10
5
 IU/mL tested 
positive to antigen. Similar results as obtained by 
Monolisa® HCV Ag-Ab ULTRA assay were also 
realized by AxSYM assay, a clear indication that 
the samples contained antibodies below the 
detectable limits possibly due to 
immunosuppression as a result of BMT. The fact 
that Monolisa® HCV Ag-Ab ULTRA assay 
detected all the BMT samples before 
transplantation, rules out the presence of antigens 
but only points towards antibody detection 
Our observations therefore suggest that the 
diagnostic performance of this “combination” 
assay is inclined towards antibody than antigen 
detection, if any. Similar findings with “combo” 
assays in HIV diagnosis have been reported (43). 
A closer look at the results obtained by Laura 
Dean’s group (44) in their evaluation of 
Monolisa® HCV Ag-Ab ULTRA assay kit using 
different panels tend to suggest the same for this 
assay. 
The overall sensitivity of 91.5% (with a 
higher sensitivity of 97.5% when BMT samples 
were excluded) and a specificity of 100% for 
Monolisa® HCV Ag-Ab ULTRA assay kit 
correspond to those reported in similar studies (42, 
45-49).The ability of this assay to distinguish as 
negative a sample which had been falsely detected 
as antibody positive-HCV-RNA negative by 
AxSYM HCV version 3.0 ELISA but categorized 
as “indeterminate” by Ortho® HCV 3.0 with 
Enhanced SAVe (and only resolved by western 
blot as negative), points towards its perfect 
discriminatory ability, hence specificity of the 
assay. Indeed, the mean absorbance value within 
the negative samples of 0.083 (0.033-0.219) was 
less than 30% of its cut off value of 0.327.  This 
performance is comparable to those of ELISA kits 
routinely used in screening for blood-transmitted 
infections such as hepatitis B virus (HBV) and 
HIV infections. Such discriminatory ability has 
also been reported by Ansaldi (41), with a 
specificity of 100% for this same assay platform 
and by Dean’s group (44). It is, however, 
important to note that the results obtained in this 
study were not from sero-conversion panels, 
where many of Monolisa® HCV Ag-Ab ULTRA 
assay kit studies has been based, and as such these 
results cannot be used conclusively to predict the 
performance of this assay kit among sero-
conversion samples. Further limitation of the 
study included low number of samples, hence the 
need for an increased number of samples. 
Although samples were also selected to reflect 
global distribution of genotypes, there is a need to 





use a large number of samples mainly from 
immunocompromised patients of African origin, 
since eventually; this assay would be more 
beneficial to limited resource settings such as in 
Sub-Saharan Africa. 
In conclusion, this study emphasizes, that 
although Monolisa® HCV Ag-Ab ULTRA assay kit 
presents an impressing sensitivity and specificity, 
the protein detection is more of antibody- than 
antigen-based. Even though we could not 
intensively test for antigen sensitivity, our results 
did not suggest any antigen sensitivity. In their 
analysis of window period samples, Laperche’s 
group suggested the implementation of this assay 
in countries where only HCV antibody screening 
is the efficient measure of improving blood safety 
(50). A closer look at their results shows a low 
sensitivity of Monolisa® HCV Ag-Ab ULTRA 
assay in RNA positive-antibody negative samples 
where only 1/3 of such samples were detected 
among blood donors and less than ½ detected in 
hemodialysis panel (50). We, therefore, suggest 
that introducing this assay to replace currently 
available “antibody only” detection kits should be 
done with caution, unless it is based on cost 
implications. Further, this assay cannot be used to 
replace Nucleic Acid based Techniques (NAT) or 
core antigen-only-based assays in routine blood 
transfusion. Finally, Monolisa® HCV Ag-Ab 
ULTRA assay cannot be used alone for HCV 
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